(Q42859155)

8 November 2017

title

Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database (English)

1 reference

8 November 2017

B. Cai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946268

2 August 2024

L. Katz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946268

2 August 2024

C. M. Alexander

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946268

2 August 2024

D. Williams-Herman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946268

2 August 2024

C. J. Girman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946268

2 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20946268

2 August 2024

publication date

1 November 2010

1 reference

full work available at URL

8 November 2017

https://doi.org/10.1111/j.1742-1241.2010.02516.x

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946268

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1742-1241.2010.02516.x

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2010.02516.x/fullpdf

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

International Journal of Clinical Practice

2 August 2024

published in

1 reference

8 November 2017

volume

64

1 reference

8 November 2017

issue

12

1 reference

8 November 2017

page(s)

1601-1608

1 reference

TZDs and Bone: A Review of the Recent Clinical Evidence

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02516.X

Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02516.X

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Projecting the future diabetes population size and related costs for the U.S.

2 August 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

The burden of mortality attributable to diabetes: realistic estimates for the year 2000

2 August 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

2 August 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Treating type 2 diabetes: how safe are current therapeutic agents?

2 August 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

2 August 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

2 August 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

2 August 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

2 August 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

2 August 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

2 August 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

2 August 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

2 August 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Channeling bias in the interpretation of drug effects

2 August 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Addressing the issue of channeling bias in observational studies with propensity scores analysis

2 August 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

The central role of the propensity score in observational studies for causal effects

2 August 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

An evaluation of the genetic-matched pair study design using genome-wide SNP data from the European population

2 August 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

2 August 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

2 August 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels

2 August 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

2 August 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

Challenges in using observational studies to evaluate adverse effects of treatment

2 August 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02516.X

2 August 2024

Identifiers

1 reference

8 November 2017

1 reference